About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

Not Yet RecruitingNCT07543731

A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab

This study aims to evaluate the long-term adherence and persistence to inclisiran and anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) in real-world clinical pra...

Lead sponsor: Novartis Pharmaceuticals•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Novartis Pharmaceuticals

CONTACT

+41613241111 novartis.email@novartis.com

Novartis Pharmaceuticals

CONTACT

Sponsors

Lead Sponsor

Novartis Pharmaceuticals

Age

18 - 99 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•A first ever prescription of injection of inclisiran, evolocumab, or alirocumab during the identification period.
•Age ≥18 years at index date.
•With at least 12 months data availability prior to index date.

Exclusion Criteria

•Patients who received either evolocumab or alirocumab as their index study drug and who were dispensed the other anti-PCSK9-mAb (alirocumab and evolocumab respectively) before the identification period.

Related studies

Health Ahead Comparative Effectiveness Study

NCT07669168 · Health Services Accessibility, Rural Health, and more

Real-life Registry in Patients With Coronary Artery Disease Treated With the SELUTION Sirolimus-eluting Balloon. Selution Iberia Registry

NCT07256249 · Cardiovascular Diseases

RECRUITINGPhase 3

A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk

NCT07613294 · Atherosclerosis, Cardiovascular Diseases, and more

RECRUITINGPhase 2/3

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

NCT05485961 · Atherosclerotic Cardiovascular Disease in Patients With ESKD

RECRUITINGPhase 4

Treatment With Aspirin After Preeclampsia: TAP Trial

NCT06281665 · Hypertensive Disorder of Pregnancy, Pre-Eclampsia, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 22, 2026Terms

Trial snapshot

StatusNOT_YET_RECRUITING

Phase—

Enrollment5,995

Start dateApr 2026

Last updatedApr 22, 2026

Condition

Cardiovascular Diseases Atherosclerotic Cardiovascular Disease Hypercholesterolemia, Familial

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 22, 2026Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions